This memo is to inform North Carolina Immunization Program (NCIP) providers of the availability of influenza vaccine and the ordering process for the 2025-2026 respiratory season. Please take time to carefully review this memo in full.
Topics Related to Immunization
The purpose of this email is to remind VFC-enrolled providers that the monoclonal antibody product nirsevimab (trade name Beyfortus® manufactured by Sanofi) will be available for ordering on Friday, August 1, 2025.
We are writing to inform you of several changes to the Vaccines for Children (VFC) program policies that may affect your practice, effective July 1, 2025.
This email is to inform you of an important update to share regarding measles reporting, testing, and vaccination.
We’re excited to announce our Provider Lunch and Learn series, a new virtual educational offering from the North Carolina Immunization Program (NCIP).
This email is to inform you that the NC Immunization Program (NCIP) received guidance that the Centers for Disease Control and Prevention (CDC) has released updated versions of the Child and Adolescent and